The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

An object of the present invention is to provide a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, a manufacturing method for the human astrocyte cell population; and an evaluation method for a test substance using the human astrocyte cell population. According to the present invention, there is provided a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, the human astrocyte cell population including at least 90% of human astrocytes, in which in the human astrocytes, a) CDKN2A is positive, b) at least one gene marker selected from the group consisting of IGFBP5, NNMT, HLA-DRB1, and HLA-DRB5 is positive, and c) an expression level of C3, which is standardized with GAPDH of a reference gene, is 0.05 copies/copies or less.

A cell culture device (1) includes: a culture vessel (10 ) that accommodates a cell suspension containing cells and a culture medium; and a stirring device (30) that is provided at a bottom part of the culture vessel (10) to stir the cell suspension accommodated in the culture vessel (10). The stirring device (30) has a shaft part (32), and a rotating part (33) rotatable with the shaft part (32) as a rotation axis. The rotating part (33) has a hole part (36) into which the shaft part (32) is inserted, and a gap (37) of 100 μm or more is secured between an interior wall demarcating the hole part (36) and the shaft part (32). A closing part (38) that closes an end part of the gap (37) in an axial direction of the rotation axis is provided.

The present invention relates to a multicellular construct that includes cells and a scaffold. The scaffold is constituted by a layered composite that comprises a gelatin nonwoven containing gelatin as a main component, and a gelatin film containing gelatin as a main component and layered on one surface of the gelatin nonwoven, and the cells are present in at least one of a region on the surface of the gelatin nonwoven and a region inside the nonwoven. The multicellular construct can be produced by arranging the scaffold in a swollen state inside the culture vessel whose inner surface is in the dry state such that the gelatin film of the scaffold is in contact with the inner bottom surface of the culture vessel, dripping a cell suspension onto the gelatin nonwoven of the scaffold, and then culturing the cells. This makes it possible to provide a multicellular construct with high seeding efficiency in which desorption of cells from a scaffold is suppressed, a method for manufacturing the same, a kit for producing the same, and a method for evaluating a compound using the same.

The invention provides methods of preparing a sample of viable diseased cells obtained from a human subject for clinical testing, wherein the methods inhibit anoikis and/or anoikis in the cells while maintaining the physiological functions and genomic composition of the cells when they were in vivo. In the methods of the invention, primary cells are cultured in media comprising at least one anoikis inhibitor, preferably at least one inhibitor of an intrinsic anoikis pathway and at least one inhibitor of an extrinsic anoikis pathway, under anti-anoikis atmospheric conditions, such as greater than 2% and less than 20% oxygen. Method combining multiple culturing conditions, including surface attachment under conditions that inhibit anoikis, are also provided. Compositions and kits for use in the methods of the invention are also provided.

The present invention relates to a device and method for automatically isolating viable cells from connective, epithelial or other tissue, and, if the tissue is multilayered, for automatically separating one tissue layer from another.

A method is provided to transform progenitor cells, fetal cells, stem cells or tumor cells, e.g., in a microfluidic device, with nucleic acid or protein.

A biomaterial preserving composition including a thermos-reversible polymer is provided. The composition is capable of solving problems related to conventional biomaterial preserving liquids not being sufficient for the survival or functional retention of cells in a biomaterial, and having many restrictions in preservation conditions such as the preservation temperature and the preservation treatment, resulting in a bottleneck for widespread use of cell therapy.

The present invention relates to an anti-DKK-1 antibody promoting growth of human dermal papilla cells and a use thereof and, more particularly, to an anti-DKK-1 antibody comprising a heavy chain CDR and a light chain CDR of specific sequences, and an antigen-binding fragment thereof, wherein the anti-DKK-1 antibody promotes the growth of human dermal papilla cells and as such, is expected to be effectively used for promoting hair growth and preventing, alleviating, or treating hair loss.

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V.sub.H, V.sub.L, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.